Primary SourceSINUVIT-NT TABLET 10'S
Brand Reference: Sinuvit NT 75mg/10mg/1500mcg Tablet
Methylcobalamin (1500mcg) + Nortriptyline (10mg) + Pregabalin (75mg)
Product Overview
Sinuvit NT 75mg/10mg/1500mcg Tablet is a combination of three medicines used to treat neuropathic pain. It works by decreasing pain by controlling calcium channel activity of the nerve cells. It also increases the level of chemical messengers in the brain that help in regulating the mood and protect nerve fibers.Sinuvit NT 75mg/10mg/1500mcg Tablet can be taken with or without food. However, it is advised to take it at the same time each day as this helps to maintain a consistent level of medicine in the body. Take this medicine in the dose and duration advised by the doctor. If you miss a dose of this medicine, take it as soon as you remember. Finish the full course of the treatment even if you feel better. It is important not to stop taking this medicine suddenly as it may worsen your symptoms.Some common side effects of this medicine include constipation, weight gain, and dryness in mouth. It may cause dizziness and sleepiness, so do not drive or do anything that requires mental focus until you know how this medicine affects you. This medicine may cause weight gain and to control it, you should have a balanced diet and exercise regularly. You must inform your doctor if you develop any unusual changes in mood or behavior, new or worsening depression, or suicidal thoughts.Before taking this medicine let your doctor know if you suffer from kidney or liver disease. Your doctor should also know about all other medicines you are taking as many of these may make this medicine less effective or change the way it works. Inform your doctor if you are pregnant, planning pregnancy or breastfeeding.
Active Composition
| Active Ingredient | Strength |
|---|---|
| Pregabalin | 75mg |
| Nortriptyline | 10mg |
| Methylcobalamin | 1500mcg |
Safety Advice & Warnings
Contraindications (When not to use)
- Alcohol: contraindicated or requires strict doctor consultation (CONSULT YOUR DOCTOR)
- Pregnancy: contraindicated or requires strict doctor consultation (CONSULT YOUR DOCTOR)
- Breast feeding: contraindicated or requires strict doctor consultation (CONSULT YOUR DOCTOR)
- Driving: contraindicated or requires strict doctor consultation (UNSAFE)
Precautions & Advisories
- Alcohol: It is not known whether it is safe to consume alcohol with Sinuvit NT 75mg/10mg/1500mcg Tablet. Please consult your doctor.
- Pregnancy: Sinuvit NT 75mg/10mg/1500mcg Tablet is not recommended during pregnancy as there is positive evidence of fetal risk based on animal studies. However, it may still be prescribed by a doctor in situations where the benefits outweigh the risks.
- Breast feeding: Sinuvit NT 75mg/10mg/1500mcg Tablet may be unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby. It should be used only if the expected benefit outweighs the potential risk. Please consult your doctor.
- Driving: Sinuvit NT 75mg/10mg/1500mcg Tablet may decrease alertness, affect your vision, or make you feel sleepy and dizzy. Do not drive if these symptoms occur.As Sinuvit NT 75mg/10mg/1500mcg Tablet may affect your alertness which may affect your ability to drive.
- Kidney: Sinuvit NT 75mg/10mg/1500mcg Tablet should be used with caution in patients with severe kidney disease. Dose adjustment may be needed.
- Liver: Sinuvit NT 75mg/10mg/1500mcg Tablet should be used with caution in patients with severe liver disease. Dose adjustment may be needed.
Frequently Asked Questions
Specifications Sheet
- Brand Name
- Sinuvit NT 75mg/10mg/1500mcg Tablet
- Generic Name (Salt)
- Methylcobalamin (1500mcg) + Nortriptyline (10mg) + Pregabalin (75mg)
- Manufacturer
- Ozone Pharmaceuticals Ltd
- Dosage Form
- tablet
- Strength
- 1500mcg/10mg/75mg
- Therapeutic Category
- NEURO CNS
- HSN Code
- 3004
Big Seal Pharma Guarantee
- Licensed wholesale distributor credentials assured on invoice.
- PAN India cold-chain logistics and secure freight delivery.
